ADAR1 Capital Management’s Dyne Therapeutics DYN Stock Holding History

ADAR1 Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$951K	Sell	42,821 -4,642	-10%	-$86.3K	0.04%	172
2026 Q1	$861K	Buy	47,463 +4,789	+11%	+$82.6K	0.05%	175
2025 Q4	$835K	Buy	42,674 +5,011	+13%	+$94.9K	0.06%	147
2025 Q3	$476K	Buy	37,663 +14,600	+63%	+$167K	0.04%	140
2025 Q2	$220K	Sell	23,063 -7,036	-23%	-$77.5K	0.03%	153
2025 Q1	$315K	Buy	+30,099	New	+$431K	0.06%	128
2024 Q4	–	Sell	-400	Closed	-$14.4K	–	240
2024 Q3	$14.4K	Buy	+400	New	+$15.9K	﹤0.01%	249
2024 Q2	–	Sell	-297	Closed	-$8.43K	–	284
2024 Q1	$8.43K	Buy	+297	New	+$6.72K	﹤0.01%	232

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ADAR1 Capital Management's DYN Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Dyne Therapeutics (DYN) stake by 9.8% in Q2 2026, selling an estimated $86.3K and leaving 42,821 shares worth $951K. The position accounts for 0.04% of the portfolio, ranked #172.

ADAR1 Capital Management first reported a position in DYN in Q1 2024 and has held it in 8 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

ADAR1 Capital Management held 42,821 shares of Dyne Therapeutics worth $951K as of Q2 2026.
ADAR1 Capital Management sold 4,642 Dyne Therapeutics shares in Q2 2026, an estimated $86.3K.
Dyne Therapeutics made up 0.04% of ADAR1 Capital Management's portfolio in Q2 2026, its #172 holding.
ADAR1 Capital Management first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 8 quarters since.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.